Free Trial

ADC Therapeutics (ADCT) Earnings Date, Estimates & Call Transcripts

ADC Therapeutics logo
$2.50 +0.07 (+2.88%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$2.47 -0.03 (-1.04%)
As of 04:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADC Therapeutics Earnings Summary

ADC Therapeutics posted Q1 2025 earnings on May 14, 2025, reporting an EPS of -$0.36, which beat analysts' consensus estimates of -$0.38 by $0.02. Quarterly revenue was reported to be $23.03 million, above analyst estimates of $17.71 million. With a trailing EPS of -$1.45, ADC Therapeutics' earnings are expected to grow next year, from ($1.69) to ($1.52) per share.

Upcoming Q2
Earnings Date
Aug. 5Before Market OpensEstimated
Consensus EPS
(May. 14)
-$0.38
Actual EPS
(May. 14)
-$0.36 Beat By $0.02
Actual Revenue
(May. 14)
$23.03M

Q1 2025 Earnings Resources

ADCT Upcoming Earnings

ADC Therapeutics' next earnings date is estimated for Tuesday, August 5, 2025, based on past reporting schedules.

Get ADC Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ADC Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

ADCT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ADCT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ADC Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20252-$0.39-$0.29-$0.34
Q2 20252-$0.40-$0.31-$0.36
Q3 20252-$0.41-$0.35-$0.38
Q4 20252-$0.42-$0.36-$0.39

ADC Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/5/2025
(Estimated)
--------
5/14/2025Q1 2025-$0.38-$0.36+$0.02-$0.36$17.71M$23.03M
3/27/2025Q4 2024-$0.35-$0.29+$0.06-$0.29$19.01M$19.00M
11/7/2024Q3 2024-$0.36-$0.42 -$0.06-$0.42$18.76M$18.46M
8/6/2024Q2 2024-$0.44-$0.38+$0.06-$0.38$19.06M$17.41M
5/6/2024Q1 2024-$0.56-$0.56--$0.56$18.19M$18.05M
3/13/2024Q4 2023-$0.47-$1.03 -$0.56-$1.03$16.58M$16.79M
11/7/2023Q3 2023-$0.61-$0.58+$0.03-$0.58$14.57M$14.49M
8/8/2023Q2 2023-$0.44-$0.58 -$0.14-$0.58$34.77M$19.28M

ADC Therapeutics Earnings - Frequently Asked Questions

ADC Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 5th, 2025 based off last year's report dates. Learn more on ADCT's earnings history.

In the previous quarter, ADC Therapeutics (NYSE:ADCT) reported ($0.36) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.38) by $0.02. Learn more on analysts' earnings estimate vs. ADCT's actual earnings.

The conference call for ADC Therapeutics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for ADC Therapeutics's latest earnings report can be read online.
Read Transcript

ADC Therapeutics (NYSE:ADCT) has a recorded annual revenue of $75.82 million.

ADC Therapeutics (NYSE:ADCT) has a recorded net income of -$240.05 million. ADCT has generated -$1.45 earnings per share over the last four quarters.

ADC Therapeutics's earnings are expected to grow from ($1.69) per share to ($1.52) per share in the next year.

More Earnings Resources from MarketBeat



This page (NYSE:ADCT) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners